Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions.

Date publication

juillet 2025

Journal

Arthritis care & research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis

Tous les auteurs :
Barbhaiya M, Zuily S, Jannat-Khah D, Amigo MC, Andrade D, Avcin T, Bertolaccini ML, Branch DW, Costedoat-Chalumeau N, de Jesús GR, Devreese KMJ, Garcia D, Gomez Puerta JA, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Petri M, Sanna G, Sciascia S, Seshan SV, Tektonidou M, Wahl D, Willis R, Yelnik C, Hendry A, Naden R, Costenbader KH, Erkan D,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40621809

Résumé

The 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification criteria aim to identify patients with high likelihood of APS for research. Phases I/II of our four-phase methodological approach resulted in 27 candidate criteria organized in clinical and laboratory domains. Here, we summarize Phase III efforts to reduce and refine criteria using patient scenarios.

Référence

Arthritis Care Res (Hoboken). 2025 07 7;: